


- to a lack of arginine vasopressin-induced phosphorylation. *Hum Mutat.* 2009;30:E891–903.
29. de Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der Sluijs P, Mallmann R, et al. Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. *J Am Soc Nephrol.* 2005;16:2872–80.
 30. Asai T, Kuwahara M, Kurihara H, Sakai T, Terada Y, Marumo F, et al. Pathogenesis of nephrogenic diabetes insipidus by aquaporin-2 C-terminus mutations. *Kidney Int.* 2003;64:2–10.
 31. Kamsteeg EJ, Bichet DG, Konings IB, Nivet H, Lonergan M, Arthus MF, et al. Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus. *J Cell Biol.* 2003;163:1099–109.
 32. Sohara E, Rai T, Yang SS, Uchida K, Nitta K, Horita S, et al. Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. *Proc Natl Acad Sci USA.* 2006;103:14217–22.



Contents lists available at SciVerse ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

KLHL2 interacts with and ubiquitinates WNK kinases



Daiei Takahashi, Takayasu Mori, Mai Wakabayashi, Yutaro Mori, Koichiro Susa, Moko Zeniya, Eisei Sohara, Tatemitsu Rai, Sei Sasaki, Shinichi Uchida *

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan

ARTICLE INFO

Article history:

Received 25 June 2013

Available online 6 July 2013

Keywords:

WNK kinase

Kelch-like protein 2

Cullin-3

Ubiquitination

ABSTRACT

Mutations in the WNK1 and WNK4 genes result in an inherited hypertensive disease, pseudohypoaldosteronism type II (PHAII). Recently, the KLHL3 and Cullin3 genes were also identified as responsible genes for PHAII. Although we have reported that WNK4 is a substrate for the KLHL3–Cullin3 E3 ligase complex, it is not clear whether all of the WNK isoforms are regulated only by KLHL3. To explore the interaction of WNKs and other Kelch-like proteins, we focused on KLHL2 (Mayven), a human homolog of *Drosophila* Kelch that shares the highest similarity with KLHL3. We found that KLHL2, as well as KLHL3, was co-immunoprecipitated with all four WNK isoforms. The direct interaction of KLHL2 with WNKs was confirmed on fluorescence correlation spectroscopy. Co-expression of KLHL2 and Cullin3 decreased the abundance of WNK1, WNK3 and WNK4 within HEK293T cells, and a significant increase of WNK4 ubiquitination by KLHL2 and Cullin3 was observed both in HEK293T cells and in an in vitro ubiquitination assay. These results suggest that KLHL2–Cullin3 also functions as an E3-ligase for WNK isoforms within the body.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Mutations in the with-no-lysine kinase 1 (WNK1) and WNK4 genes are responsible for pseudohypoaldosteronism type II (PHAII) [1], which is characterized by hypertension, hyperkalemia, and metabolic acidosis [2]. Numerous studies have been performed to clarify the molecular pathogenesis of PHAII [3]. We have found that increased phosphorylation of oxidative stress-responsive kinase 1 (OSR1) and STE20/SPS1-related proline/alanine-rich kinase (SPAK), which are substrates of WNK kinases, results in the activation of the Na-Cl cotransporter (NCC) in vivo [4–6]. The analysis of WNK4^{-/-} mice was concordant with our hypothesis that WNK4 kinase is a major regulator of NCC phosphorylation in kidney [7].

In 2011, additional genes responsible for PHAII (KLHL3 and Cullin3) were identified [8,9]. KLHL3 is a member of the BTB-Kelch protein family, which includes components of the Cullin-RING E3 ubiquitin ligases and a substrate adaptor for ubiquitination [10–12]. Recently, we reported that KLHL3 interacted with Cullin3 and WNK4, induced WNK4 ubiquitination, and reduced WNK4 protein abundance. We also revealed the pathophysiological role of PHAII-causing mutations of the WNK4, KLHL3 and Cullin3 genes [13]. Namely, the mutations caused impaired ubiquitination and a subsequent increase of WNK4 in the kidney, which activate the WNK-OSR1/SPAK-NCC signal cascade and cause PHAII [13]. Two independent reports have supported our findings [14,15]. In

addition to WNK4, Alessi's group reported that WNK1 interacts with the KLHL3–Cullin3 complex in vitro [16]. This data is quite reasonable since we identified that the domain within WNK4 responsible for the binding to KLHL3 is an acidic domain that is highly conserved among WNK kinases [13]. Therefore, it would be possible that WNK2 and WNK3 could also be targets of KLHL3–Cullin3 E3 ligase. However, WNK isoforms are widely expressed in various cell types within the body, whereas KLHL3 expression might be relatively limited in specific cell types. In this respect, we hypothesized that there may be other ubiquitin ligases for WNK kinases. Here, we focused on KLHL2 (Mayven), another human homolog of *Drosophila* Kelch, since the Kelch domain (WNK-binding domain) of KLHL2 is highly similar (86% identity) to that of KLHL3. Initially, KLHL2 was identified as an actin-binding protein predominantly expressed in brain [17]. Later, it was found that KLHL2 formed a complex with Cullin3 and bound to and increased the ubiquitination of neuronal pentraxin with chromo domain (NPCD), suggesting its role as E3 ubiquitin ligase [18]. In the present study, we report that KLHL2 binds to WNKs at their acidic domain and functions as an E3 ubiquitin ligase for WNK kinases.

2. Materials and methods

2.1. Plasmids

Expression plasmids for 3xFLAG-tagged human WNK1, WNK4, Cullin3, Halo-tagged human WNK4 and KLHL3 have been described previously [13,19,20]. The cDNA encoding Halo-tagged

* Corresponding author. Address: 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan. Fax: +81 3 5803 5215.

E-mail address: suchida.kid@tmd.ac.jp (S. Uchida).

human WNK1, WNK2, WNK3 and GAPDH in pFN21A vector were purchased from Promega. Human KLHL2 cDNA was isolated by reverse transcription-polymerase chain reaction using human brain mRNA from human total RNA master panel II (Clontech) as a template. Sequence of the amplification primers employed is as follows: KLHL2 sense, 5'-ATC GAT CGA TAT GGA GAC GCC GCC GCT GCC-3'; KLHL2 antisense, 5'-CCG GCG CGC CGT TTA AAC TCA TAA TGG TTT ATC AAT AAC-3'. The cDNA was cloned into pFN21A vector (Promega). HA₄-tagged ubiquitin expression vector was kindly provided by T. Ohta (St. Marianna University, School of Medicine).

2.2. Reverse transcription polymerase chain reaction

RNAs from human total RNA master panel II (Clontech) were reverse-transcribed by using Omniscript RT kit (QIAGEN). The target cDNAs were amplified by PCR, which was performed by using primers described below. The primers for GAPDH were purchased from Roche Diagnostics. Sequence of the amplification primers employed is as follows: KLHL2 sense, 5'-TAA TAC CGA AAA ACA CTG CC-3'; KLHL2 antisense, 5'-TTC TAA CTC TCT TTG CTC GG-3'; KLHL3 sense, 5'-TGA CAA GAA CCA GAG GAC GA-3'; KLHL3 antisense, 5'-AAC TGA GAC TGC AGG AAG-3'.

2.3. Cell culture and transfections

HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin at 37 °C in a humidified 5% CO₂ incubator. HEK293T cells (3 × 10⁵ cells/6-cm dish) were transfected by the indicated amount of plasmid DNA with Lipofectamine 2000 reagent (Invitrogen).

2.4. Immunoprecipitation

HEK293T cells transfected with the indicated amount of DNA were lysed in a buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 1 mM sodium orthovanadate, 50 mM sodium fluoride, and protease inhibitor cocktail) for 30 min at 4 °C. When the cells were transfected with the HA-ubiquitin expression plasmid, the cells were treated with 1 μM epoxomicin (specific and irreversible proteasome inhibitor; Peptide Institute, Osaka, Japan) for 3 h before harvesting. After centrifugation at 12,000×g for 15 min, the protein concentration of the supernatants was measured and equal amounts of the supernatants were used for immunoprecipitation with anti-FLAG M2 beads (Sigma-Aldrich) for 1 h at 4 °C. Thereafter, the precipitants were washed with the lysis buffer and the immunoprecipitates were eluted in SDS sample buffer after boiling for 5 min. To detect ubiquitination of WNK4 in denatured samples, the cells transfected with various plasmids were lysed in 2% SDS buffer (2% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 2 mM sodium orthovanadate, 50 mM sodium fluoride, 1× protease inhibitors) and boiled for 10 min followed by sonication. Before immunoprecipitation, the lysates were diluted 1:10 in a dilution buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100), incubated at 4 °C for 1 h with rotation, and centrifuged at 12,000×g for 15 min.

2.5. Immunoblotting

Cells transfected with the indicated amount of plasmid DNA were lysed in lysis buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 1 mM sodium orthovanadate, 50 mM sodium fluoride, and protease inhibitor cocktail (Roche Diagnostics)] for 30 min at 4 °C. After centrifugation at 12,000×g for 15 min, the supernatants were boiled with SDS sample-buffer (Cosmo Bio,

Inc.) and subjected to SDS-PAGE. Blots were probed with the following primary antibodies: anti-FLAG (Sigma-Aldrich), anti-Halo (Promega), anti-HA (Merck Millipore), anti-T7 (Merck Millipore) and anti-actin (Cytoskeleton) antibodies. Alkaline-phosphatase-conjugated anti-IgG antibodies (Promega, Madison, WI) and WesternBlue (Promega) were used to detect the signals.

2.6. In vitro ubiquitination assay

GST-WNK4(490–626) in pGEX6p-1 vector was described previously [13]. Recombinant GST-fusion WNK4 protein was expressed in BL21 *Escherichia coli* cells and purified by using glutathione sepharose beads. KLHL2 or KLHL3 complexes were immunoprecipitated from the lysates of HEK293T cells transiently expressing FLAG-KLHL2 or FLAG-KLHL3. Then, the complexes were incubated in a 20 μl volume of reaction buffer (50 mM Tris-HCl, pH 7.4, 2.5 mM MgCl₂, 0.5 mM DTT, 2 mM ATP) for 2 h at 30 °C with purified GST-WNK4-His (1 μg), 100 ng recombinant human E1 (Boston Biochem), 500 ng recombinant human UbcH5a/UBE2D1 (Boston Biochem), and 2.5 μg recombinant human ubiquitin (Boston Biochem). The reaction was terminated by addition of SDS-PAGE sample buffer, followed by boiling for 5 min. The reaction mixtures were then subjected to immunoblot analyses with anti Ub (Cell Signaling Technology) or His (Abcam) antibodies.

2.7. Fluorescence correlation spectroscopy

Fluorescent TAMRA-labeled WNK1, 2, 3 and WNK4 peptides covering the PHAI mutation sites were prepared (Hokkaido System Science Co., Ltd., Hokkaido, Japan). Kelch-repeats of human KLHL2 or KLHL3 were cloned into pGEX6P-1 vector. Recombinant GST-fusion KLHL proteins were expressed in BL21 *E. coli* cells and purified by using glutathione sepharose beads. The TAMRA-labeled WNK peptides were incubated at room temperature for 30 min with different concentrations of GST-KLHL proteins (0–2 μM) in 1× PBS with 0.05% Tween 20 reaction buffer and the fluorescence correlation spectroscopy (FCS) measurements of single-molecule fluorescence were performed using the FluoroPoint-light analytical system (Olympus, Tokyo, Japan) [21]. The assay was performed in a 384-well plate. All experiments were performed in 10 s of data acquisition time and the measurements were repeated five times per sample. The amino acid sequence of TAMRA-WNKs is as follows: WNK1, TAMRA-SVSTQVEPEPEADQHQQLYQQPSISVLS (30 aa); WNK2, TAMRA-GQGPPEPEPEADQHLLPPTLPTSATSLA (30 aa); WNK3, TAMRA-AQQTGAECETEVDQHVRRQLLRKPQQHC (30 aa); WNK4, TAMRA-PSVFPPEPEPEADQHPFLFRHASYSSST (30 aa). Acidic domains of each WNK isoform are underlined.

2.8. Statistics

Statistical significance was evaluated by ANOVA test with multiple comparisons using Tukey's correction. The results with *p* values <0.05 were considered statistically significant. Data are presented as mean ± SEM.

3. Results

3.1. Expression pattern of KLHL2 and KLHL3 in human organs

To examine the distribution of KLHL2 and KLHL3 expression, we performed RT-PCR of KLHL2 and KLHL3 cDNA in human organs (Fig. 1). cDNA from the indicated human tissues was used as a template for PCR by using primers specific for KLHL2, KLHL3 and GAPDH mRNA. KLHL2 as well as KLHL3 was expressed differently in various human organs.

3.2. Overexpressed KLHL2 interacts with WNK kinases

We first confirmed the interaction of KLHL2 and Cullin3 by co-immunoprecipitation (Fig. 2A) as previously reported [18]. To investigate whether KLHL2 interacts with WNK kinases in mammalian cells, we then performed co-immunoprecipitation assays of full-length KLHL2 and KLHL3 with WNK kinases. Because the expression level of Halo-tagged WNK1 was low, we used FLAG-tagged WNK1 in co-immunoprecipitation assays (Fig. 2B). Other WNKs were Halo-tagged (Fig. 2C). We found that KLHL3 could interact with WNK2 and WNK3 as well as WNK1 and WNK4 and that KLHL2 could also interact with all WNK kinases. As in the case with KLHL3, KLHL2 was not co-immunoprecipitated with other components of the WNK-OSR1/SPAK-NCC signal cascade, i.e., OSR1, SPAK, and NCC (Fig. S1).

To investigate whether the conserved acidic domains of WNKs could be the common binding sites for KLHL2 and KLHL3, we prepared TAMRA-labeled WNK peptides covering each acidic motif (Fig. 2D), and the binding to the Kelch-repeat of KLHL2 or KLHL3 proteins was assayed *in vitro* as we described previously [13]. As shown in Fig. 2D, the diffusion time of TAMRA-labeled peptide became slower as the concentration of GST-KLHLs increased, indicating that all WNK peptides could bind to both GST-KLHL2 and GST-KLHL3. GST alone did not affect the diffusion time. It is notable that the WNK3 peptide showed the slowest diffusion time both with KLHL2 and KLHL3. The amino acid sequence of the WNK3 acidic motif (ECEETEVDQH) was different from those of other WNK kinases (EPEEPEADQH) (Fig. 2D), which might be responsible for the difference in diffusion times.

3.3. KLHL2 regulated the abundance of WNK kinases

To determine the effect of KLHL2 on WNK kinases, we overexpressed KLHL2 or KLHL3 plus Cullin3 along with WNK kinases in HEK293T cells. As shown in Fig. 3, co-expression of KLHL2 or KLHL3 with Cullin3 decreased the levels of WNK1, WNK3, and WNK4 proteins as compared to the expression of Cullin3 alone. In contrast to WNK1, 3, and 4, the effect of KLHL2 on WNK2 was not clear, even after repeating the experiments more than three times.




Fig. 1. Expression of KLHL2 and KLHL3 mRNAs in human organs. Complementary DNAs from the indicated human organs were used as a template for PCR using primers specific for KLHL2, KLHL3 and GAPDH mRNA. The expression patterns of KLHL2 and KLHL3 are different.

3.4. KLHL2 increases the ubiquitination of WNK4

To investigate whether KLHL2 ubiquitinates WNK kinases, we first performed an *in vitro* ubiquitination assay. FLAG-tagged KLHL2 or KLHL3 expressed in HEK293T cells was immunoprecipitated with M2-agarose and mixed with recombinant E1, E2, ubiquitin, and WNK4 protein (residues 490–626). We did not overexpress Cullin3, since we knew from the preliminary experiments that there was a sufficient amount of endogenous Cullin3 in HEK293T cells to perform this assay (data not shown). We confirmed that KLHL2 directly ubiquitinated WNK4 protein (residues 490–626) (Fig. 4A) as KLHL3 did in our previous study. We also confirmed WNK4 ubiquitination *in vivo* by immunoprecipitation under a denaturing condition. As shown in the ubiquitin (HA) immunoblot (Fig. 4B), the ubiquitination signals appeared as a smeared band over the apparent molecular size of WNK4 (200 kDa). This ubiquitination was increased by co-expression of KLHL2 or KLHL3, although the immunoprecipitated WNK4 was decreased by co-expression. These results clearly indicate that KLHL2 functions as an E3 ubiquitin ligase of WNK4.

4. Discussion

In the present study, we reported the interaction between KLHL2 and WNK kinases that induced the ubiquitination of WNK protein, leading to a reduced level of WNK protein in cells. KLHL2 was initially identified as an actin-binding protein highly expressed in the brain [17], and it was implicated in oligodendrocyte process outgrowth as well as transcriptional regulation of growth-promoting factors in breast cancer cells [22–24]. However, several members of the Kelch-like protein family have been recently described as components of multi-protein complexes known as Cullin-RING E3 ubiquitin ligases (CRLs) [10,11,25]. CRLs are involved in the identification and targeting of proteins for ubiquitination. Kelch-like proteins function as substrate adapters, recruiting proteins destined for ubiquitination into the CRL complex. In line with this notion, neuronal pentraxin with chromo domain (NPCD) was reported to bind to KLHL2, and its ubiquitination was increased by KLHL2 co-expression [18]. However, no direct evidence showing that KLHL2 is an E3 ligase has been demonstrated.

We observed a highly similar function of KLHL2 to that of KLHL3 as an E3 ubiquitin ligase to WNK kinases. KLHL2 is the closest homolog of KLHL3 among the KLHL proteins, and it is also the closest homolog of drosophila Kelch (63% identity). The Kelch repeats among these three proteins are highly conserved. The four β -strands found in each Kelch repeat are named 'a' to 'd'. It is surprising that not only all of the mutated residues reported in PHAII patients [8,9] are conserved between these three Kelch-like proteins, but also that KLHL2 shares almost perfect identity (98% identity) with KLHL3 when focused on its 'b-c' loops and 'd-a' loops, in which most of the PHAII-causing KLHL3 mutations cluster [8,9]. This high identity between KLHL2 and KLHL3 is not seen between KLHL3 and other Kelch-like proteins [26]. The function of each loop of the KLHL3 Kelch repeat has not been evaluated yet, but considering that the 'd-a' loops and 'b-c' loops of Keap1 form the top face of the β -propeller and that this face is the substrate (Nrf2)-binding pocket [27], the extensive shared identity in these domains between KLHL2 and KLHL3 may support the identity of substrate specificity between KLHL2 and KLHL3.

This study clearly shows that not only WNK1 and WNK4 but all WNK kinases could be regulated by KLHL3. In addition, KLHL2 could regulate all WNKs as well. In the case of WNK4, the dysregulation of WNK4 degradation significantly affected the downstream signaling and caused PHAII. In this respect, the regulation




Fig. 2. KLHL2 interacted with Cullin3 and WNK kinases. (A) FLAG-tagged Cullin3 was co-immunoprecipitated with Halo-tagged KLHL2 as well as KLHL3 in HEK293T cells. (B) Halo-tagged KLHL2 and KLHL3 were co-immunoprecipitated with FLAG-tagged WNK1. (C) FLAG-tagged KLHL2 and KLHL3 were co-immunoprecipitated with Halo-tagged WNK2, WNK3 and WNK4. (D) Diffusion time of a single-molecule TAMRA-labeled peptide corresponding to the acidic domain of wild-type WNK kinases was measured by fluorescence correlation spectroscopy. The diffusion time of each peptide was significantly ($p < 0.05$) increased with KLHL2-GST at 0.21 μM or higher and KLHL3-GST at 0.14 μM or higher, but not with GST alone. These data indicate the direct binding of the Kelch-repeat of KLHL2 and KLHL3 to the acidic domain of WNK kinases.




Fig. 3. KLHL2 regulated WNK kinase abundance. (A) FLAG-tagged WNK1 and FLAG-tagged Cullin3 were co-expressed with Halo-tagged KLHL2 or KLHL3. Co-expression of KLHL2 as well as KLHL3 decreased the abundance of WNK1. (B) Halo-tagged WNK kinases and FLAG-tagged Cullin3 were co-expressed with Halo-tagged GAPDH, KLHL2 or KLHL3. The cellular WNK3 and WNK4 abundance were decreased by co-expression of KLHL2 or KLHL3. The WNK2 was not affected by the co-expression. (C) Densitometric analysis of the results of (A) and (B). **p* < 0.05 compared with control.




Fig. 4. KLHL2 increased WNK4 ubiquitination. (A) In vitro ubiquitination assay of WNK4. WNK4 (490–626) (50 kDa) was incubated with ubiquitin, E1 and E2 (UbcH5a/UBE2D1) with or without KLHL2–Cullin3 or KLHL3–Cullin3 complex. KLHL2 as well as KLHL3 significantly ubiquitinated WNK4 (490–626) in vitro. (B) WNK4 was expressed with HA-ubiquitin and KLHL2 or KLHL3, and immunoprecipitated under a denaturing condition. As shown in the ubiquitin (HA) immunoblot, the ubiquitination signals were observed as a smeared band over the apparent molecular size of WNK4 (200 kDa). The ubiquitination of WNK4 was increased by co-expression of KLHL2 or KLHL3.

of other WNKs by KLHL2 and/or KLHL3 may be involved in certain pathophysiological conditions in extrarenal tissues.

In summary, we have identified the function of KLHL2 as an E3 ubiquitin ligase for WNK kinases. Different combinations of KLHL2 and KLHL3 with WNKs could regulate WNK kinase signaling in different kinds of cells.

Acknowledgments

This study was supported in part by Grants-in-Aid for Scientific Research (A) from the Japan Society for the Promotion of Science, Health Labor Science Research Grant from the Ministry of Health Labor and Welfare, Salt Science Research Foundation (Nos. 1026, 1228), and Takeda Science Foundation.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bbrc.2013.06.104>.

References

[1] F.H. Wilson, S. Disse-Nicodème, K.A. Choate, K. Ishikawa, C. Nelson-Williams, I. Desitter, M. Gunel, D.V. Milford, G.W. Lipkin, J.M. Achard, M.P. Feely, B. Dussol, Y. Berland, R.J. Unwin, H. Mayan, D.B. Simon, Z. Farfel, X. Jeunemaitre, R.P. Lifton, Human hypertension caused by mutations in WNK kinases, *Science* 293 (2001) 1107–1112.

[2] R.D. Gordon, The syndrome of hypertension and hyperkalemia with normal glomerular filtration rate: Gordon's syndrome, *Aust. N.Z. J. Med.* 16 (1986) 183–184.

- [3] C. Richardson, D.R. Alessi, The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway, *J. Cell Sci.* 121 (2008) 3293–3304.
- [4] S.S. Yang, T. Morimoto, T. Rai, M. Chiga, E. Sohara, M. Ohno, K. Uchida, S.H. Lin, T. Moriguchi, H. Shibuya, Y. Kondo, S. Sasaki, S. Uchida, Molecular pathogenesis of pseudohypoaldosteronism type II: generation and analysis of a Wnk4(D561A/+) knockin mouse model, *Cell Metab.* 5 (2007) 331–344.
- [5] M. Chiga, T. Rai, S.S. Yang, A. Ohta, T. Takizawa, S. Sasaki, S. Uchida, Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone, *Kidney Int.* 74 (2008) 1403–1409.
- [6] A. Ohta, T. Rai, N. Yui, M. Chiga, S.S. Yang, S.H. Lin, E. Sohara, S. Sasaki, S. Uchida, Targeted disruption of the Wnk4 gene decreases phosphorylation of Na-Cl cotransporter, increases Na excretion and lowers blood pressure, *Hum. Mol. Genet.* 18 (2009) 3978–3986.
- [7] M. Castañeda-Bueno, L.G. Cervantes-Pérez, N. Vázquez, N. Uribe, S. Kantesaria, L. Morla, N.A. Bobadilla, A. Doucet, D.R. Alessi, G. Gamba, Activation of the renal Na⁺-Cl⁻ cotransporter by angiotensin II is a WNK4-dependent process, *Proc. Natl. Acad. Sci. USA* 109 (2012) 7929–7934.
- [8] L.M. Boyden, M. Choi, K.A. Choate, C.J. Nelson-Williams, A. Farhi, H.R. Toka, I.R. Tikhonova, R. Bjornson, S.M. Mane, G. Colussi, M. Lebel, R.D. Gordon, B.A. Semmekrot, A. Poujol, M.J. Välimäki, M.E. De Ferrari, S.A. Sanjad, M. Gutkin, F.E. Karet, J.R. Tucci, J.R. Stockigt, K.M. Keppler-Noreuil, C.C. Porter, S.K. Anand, M.L. Whiteford, I.D. Davis, S.B. Dewar, A. Bettinelli, J.J. Fadrowski, C.W. Belsha, T.E. Hunley, R.D. Nelson, H. Trachtman, T.R. Cole, M. Pinsky, D. Bockenhauer, M. Shenoy, P. Vaidyanathan, J.W. Foreman, M. Rasoulpour, F. Thameem, H.Z. Al-Shahroui, J. Radhakrishnan, A.G. Gharavi, B. Goilav, R.P. Lifton, Mutations in kelch-like 3 and Cullin 3 cause hypertension and electrolyte abnormalities, *Nature* 482 (2012) 98–102.
- [9] H. Louis-Dit-Picard, J. Barc, D. Trujillano, S. Miserey-Lenkei, N. Bouatia-Naji, O. Pylypenko, G. Beaurain, A. Bonnefond, O. Sand, C. Simian, E. Vidal-Petiot, C. Soukaseum, C. Mandet, F. Broux, O. Chabre, M. Delahousse, V. Esnault, B. Fiquet, P. Houillier, C.I. Bagnis, J. Koenig, M. Konrad, P. Landais, C. Mourani, P. Niaudet, V. Probst, C. Thauvin, R.J. Unwin, S.D. Soroka, G. Ehret, S. Ossowski, M. Caulfield, P. Bruneval, X. Estivill, P. Froguel, J. Hadchouel, J.J. Schott, X. Jeunemaitre, I.C.f.B.P. (ICBP), KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron, *Nat. Genet.* 44 (2012) 456–460. S451–S453.
- [10] M. Furukawa, Y. Xiong, BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase, *Mol. Cell. Biol.* 25 (2005) 162–171.
- [11] Y.R. Lee, W.C. Yuan, H.C. Ho, C.H. Chen, H.M. Shih, R.H. Chen, The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses, *EMBO J.* 29 (2010) 1748–1761.
- [12] M.Y. Lin, Y.M. Lin, T.C. Kao, H.H. Chuang, R.H. Chen, PDZ-RhoGEF ubiquitination by Cullin3–KLHL20 controls neurotrophin-induced neurite outgrowth, *J. Cell Biol.* 193 (2011) 985–994.
- [13] M. Wakabayashi, T. Mori, K. Isobe, E. Sohara, K. Susa, Y. Araki, M. Chiga, E. Kikuchi, N. Nomura, Y. Mori, H. Matsuo, T. Murata, S. Nomura, T. Asano, H. Kawaguchi, S. Nonoyama, T. Rai, S. Sasaki, S. Uchida, Impaired KLHL3-mediated ubiquitination of WNK4 causes human hypertension, *Cell Rep.* 3 (2013) 858–868.
- [14] S. Shibata, J. Zhang, J. Puthumana, K.L. Stone, R.P. Lifton, Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4, *Proc. Natl. Acad. Sci. USA* (2013) 7838–7843.
- [15] G. Wu, J.B. Peng, Disease-causing mutations in KLHL3 impair its effect on WNK4 degradation, *FEBS Lett.* (2013) 1717–1722.
- [16] A. Ohta, F.R. Schumacher, Y. Mehellou, C. Johnson, A. Knebel, T.J. Macartney, N.T. Wood, D.R. Alessi, T. Kurz, The CUL3–KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction, *Biochem. J.* 451 (2013) 111–122.
- [17] M. Soltysik-Espanola, R.A. Rogers, S. Jiang, T.A. Kim, R. Gaedigk, R.A. White, H. Avraham, S. Avraham, Characterization of Mayven, a novel actin-binding protein predominantly expressed in brain, *Mol. Biol. Cell* 10 (1999) 2361–2375.
- [18] L.A. Tseng, J.L. Bixby, Interaction of an intracellular pentraxin with a BTB–Kelch protein is associated with ubiquitylation, aggregation and neuronal apoptosis, *Mol. Cell. Neurosci.* 47 (2011) 254–264.
- [19] K. Yamauchi, T. Rai, K. Kobayashi, E. Sohara, T. Suzuki, T. Itoh, S. Suda, A. Hayama, S. Sasaki, S. Uchida, Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins, *Proc. Natl. Acad. Sci. USA* 101 (2004) 4690–4694.
- [20] A. Ohta, S.S. Yang, T. Rai, M. Chiga, S. Sasaki, S. Uchida, Overexpression of human WNK1 increases paracellular chloride permeability and phosphorylation of claudin-4 in MDCKII cells, *Biochem. Biophys. Res. Commun.* 349 (2006) 804–808.
- [21] K. Kuroki, S. Kobayashi, M. Shiroishi, M. Kajikawa, N. Okamoto, D. Kohda, K. Maenaka, Detection of weak ligand interactions of leukocyte Ig-like receptor B1 by fluorescence correlation spectroscopy, *J. Immunol. Methods* 320 (2007) 172–176.
- [22] P. Montague, P.G. Kennedy, S.C. Barnett, Subcellular localization of Mayven following expression of wild type and mutant EGFP tagged cDNAs, *BMC Neurosci.* 11 (2010) 63.
- [23] S. Jiang, H.K. Avraham, S.Y. Park, T.A. Kim, X. Bu, S. Seng, S. Avraham, Process elongation of oligodendrocytes is promoted by the Kelch-related actin-binding protein Mayven, *J. Neurochem.* 92 (2005) 1191–1203.
- [24] X. Bu, H.K. Avraham, X. Li, B. Lim, S. Jiang, Y. Fu, R.G. Pestell, S. Avraham, Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells, *Oncogene* 24 (2005) 2398–2409.
- [25] S. Angers, C.J. Thorpe, T.L. Biechele, S.J. Goldenberg, N. Zheng, M.J. MacCoss, R.T. Moon, The KLHL12–Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation, *Nat. Cell Biol.* 8 (2006) 348–357.
- [26] S. Prag, J.C. Adams, Molecular phylogeny of the kelch-repeat superfamily reveals an expansion of BTB/kelch proteins in animals, *BMC Bioinformatics* 4 (2003) 42.
- [27] S.C. Lo, X. Li, M.T. Henzl, L.J. Beamer, M. Hannink, Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling, *EMBO J.* 25 (2006) 3605–3617.

Impaired KLHL3-Mediated Ubiquitination of WNK4 Causes Human Hypertension

Mai Wakabayashi,^{1,4} Takayasu Mori,^{1,4} Kiyoshi Isobe,¹ Eisei Sohara,¹ Koichiro Susa,¹ Yuya Araki,¹ Motoko Chiga,¹ Eriko Kikuchi,¹ Naohiro Nomura,¹ Yutaro Mori,¹ Hiroshi Matsuo,² Tomohiro Murata,² Shinsuke Nomura,² Takako Asano,³ Hiroyuki Kawaguchi,³ Shigeaki Nonoyama,³ Tatemitsu Rai,¹ Sei Sasaki,¹ and Shinichi Uchida^{1,*}

¹Department of Nephrology, Graduate Schools of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan

²Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan

³Department of Pediatrics, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan

⁴These authors contributed equally to this work

*Correspondence: suchida.kid@tmd.ac.jp

<http://dx.doi.org/10.1016/j.celrep.2013.02.024>

SUMMARY

Mutations in WNK kinases cause the human hypertensive disease pseudohypoaldosteronism type II (PHAII), but the regulatory mechanisms of the WNK kinases are not well understood. Mutations in kelch-like 3 (*KLHL3*) and *Cullin3* were also recently identified as causing PHAII. Therefore, new insights into the mechanisms of human hypertension can be gained by determining how these components interact and how they are involved in the pathogenesis of PHAII. Here, we found that *KLHL3* interacted with *Cullin3* and *WNK4*, induced *WNK4* ubiquitination, and reduced the *WNK4* protein level. The reduced interaction of *KLHL3* and *WNK4* by PHAII-causing mutations in either protein reduced the ubiquitination of *WNK4*, resulting in an increased level of *WNK4* protein. Transgenic mice overexpressing *WNK4* showed PHAII phenotypes, and *WNK4* protein was indeed increased in *Wnk4*^{D561A/+} PHAII model mice. Thus, *WNK4* is a target for *KLHL3*-mediated ubiquitination, and the impaired ubiquitination of *WNK4* is a common mechanism of human hereditary hypertension.

INTRODUCTION

Hypertension is one of the biggest health problems in the industrialized world because it damages critical organs. Studies of monogenic hypertensive diseases, such as Liddle syndrome (Shimkets et al., 1994) and pseudohypoaldosteronism type II (PHAII) (Achard et al., 2001), have provided new insight into the mechanisms of blood pressure regulation in humans. Liddle syndrome is caused by mutations in the epithelial sodium channel (ENaC) that increase the amount of ENaC in the apical membranes of collecting ducts in the kidney through the impairment of ENaC ubiquitination, thereby increasing sodium reabsorption (Rossier and Schild, 2008). PHAII is another autosomal-dominant hereditary hypertensive disease that is characterized by hyperkalemia and metabolic acidosis (Gordon, 1986),

and genes encoding the WNK kinases (*WNK1* and *WNK4*) were identified in 2001 as responsible (Wilson et al., 2001). However, the pathogenesis of PHAII was totally unknown when the WNK genes were identified. Since then, numerous in vitro and in vivo studies have been performed for clarifying the molecular pathogenesis of PHAII (Bergaya et al., 2011; Laloti et al., 2006; Liu et al., 2011; McCormick and Ellison, 2011; Yang et al., 2003). We generated a mouse model of PHAII carrying the same mutation as patients with PHAII (*Wnk4*^{D561A/+} knockin mouse) (Yang et al., 2007) and discovered that the constitutive activation of a novel signal cascade, consisting of WNK kinases, OSR1 and SPAK kinases, and the Na-Cl cotransporter (NCC), is the major pathogenic mechanism of PHAII (Chiga et al., 2008, 2011). However, the molecular pathogenesis of how the missense mutation of *WNK4* activates the cascade remains to be clarified.

Recently, two new genes (*KLHL3* and *Cullin3*) were also identified as being associated with PHAII (Boyden et al., 2012; Louis-Dit-Picard et al., 2012). However, how these genes are involved in PHAII is unknown. Determining how these responsible genes (*WNK*, *KLHL3*, and *Cullin3*) are orchestrated and how pathogenic mutations in these genes cause a common hypertensive disease will contribute to the understanding of the molecular pathogenesis of human hypertension and also to the identification of new targets for antihypertensive drugs.

The purpose of the present study was to determine the pathogenic role of PHAII-causing mutations in the *WNK4*, *KLHL3*, and *Cullin3* genes. We found that *WNK4* kinase is a substrate of *KLHL3*-*Cullin3*-targeted ubiquitination and that the PHAII-causing mutations of *WNK4* and *KLHL3* resulted in impaired *WNK4* ubiquitination. The resultant increase in the *WNK4* level was confirmed in *Wnk4*^{D561A/+} PHAII model mice; this increase constitutively activates the WNK-OSR1/SPAK-NCC signal cascade and causes PHAII. Data from *WNK4* transgenic mice were consistent with this idea.

RESULTS

KLHL3 Interacted with and Regulated the Abundance of *WNK4* Kinase Protein

We have reported that the activation of the WNK-OSR1/SPAK-NCC signal cascade is the major pathogenic mechanism of PHAII caused by a *WNK4* mutation (Yang et al., 2007), and




Figure 1. KLHL3 Was Coimmunoprecipitated with Cullin3 and WNK4

(A) FLAG-tagged Cullin3 (CUL3) was coimmunoprecipitated with Halo-tagged KLHL3 in HEK293T cells. IB, immunoblot; IP, immunoprecipitation.

(B) T7-tagged WNK4, OSR1, SPAK, and NCC were coexpressed with Halo-tagged KLHL3 in HEK293T cells and immunoprecipitated with T7 antibody. KLHL3 was coimmunoprecipitated only with WNK4. The asterisks indicate T7-tagged proteins.

(C) WNK4 was coimmunoprecipitated with endogenous Cullin3 in HEK293T cells in the presence of KLHL3 coexpression. Results similar to those shown in (A), (B), and (C) were obtained in three separate experiments.

mutations in the *KLHL3* and *Cullin3* genes were also reported as causing the same PHAII phenotypes (Boyden et al., 2012; Louis-Dit-Picard et al., 2012). These data suggest that KLHL3 and Cullin3 may somehow interact with the components of the WNK-OSR1/SPAK-NCC signal cascade. Because KLHL proteins function as substrate adaptors in Cullin3-based E3 ligase (Cirak et al., 2010; Kigoshi et al., 2011; Lee et al., 2010; Lin et al., 2011), we first confirmed a complex formation of KLHL3 and Cullin3 via coimmunoprecipitation (Figure 1A). We then investigated whether KLHL3 interacted with the components of the WNK-OSR1/SPAK-NCC signal cascade. To verify this, we performed coimmunoprecipitation assays of KLHL3 with WNK4, OSR1, SPAK, and NCC. As shown in Figure 1B, KLHL3 was coimmunoprecipitated with WNK4, but not with OSR1, SPAK, or NCC. The interaction of Cullin3 with WNK4 was also confirmed through coimmunoprecipitation when KLHL3 was overexpressed (Figure 1C), consistent with the previously reported role of KLHL proteins as substrate adaptors in the Cullin3-based ubiquitin E3 ligase (Cirak et al., 2010; Kigoshi et al., 2011; Lee et al., 2010; Lin et al., 2011). We tried to demonstrate coimmunoprecipitation of endogenous WNK4 and KLHL3 in kidney tissue and in cultured cells. However, this was not successful due to the relatively low level of expression of WNK4 in cultured cells and the lack of KLHL3 antibodies adequate for immunoprecipitation. The finding that WNK4 might be readily degraded by the binding to KLHL3 within cells as shown below also made the detection of coimmunoprecipitation difficult, especially in kidney samples.

To clarify the functional role of KLHL3 on WNK4, we overexpressed KLHL3 along with WNK4. As shown in Figure 2A, KLHL3 overexpression dramatically decreased WNK4 protein expression, even when overexpressed by a strong cytomegalovirus (CMV) promoter. The expression level of bacterial alkaline phosphatase (BAP) driven by the same promoter was not affected by KLHL3 coexpression. OSR1, SPAK, and NCC

expression levels were also not affected by KLHL3 coexpression (Figure 2B), supporting the results from the coimmunoprecipitation. To confirm the effect of KLHL3 on WNK4, we evaluated this effect on the endogenous WNK4 in mpkDCT cells, a mouse distal-tubule-derived cell line (Duong Van Huyen et al., 2001) (Figure 2C). Wild-type KLHL3 significantly decreased the endogenous WNK4 protein level. Conversely, KLHL3 knockdown significantly increased the WNK4 protein level (Figure 2D). Although these effects of KLHL3 expression on WNK4 were observed without Cullin3 overexpression, we further tested the effect of Cullin3 overexpression on WNK4 in human embryonic kidney 293T (HEK293T) cells. As shown in Figure 2E, coexpression of Cullin3 with KLHL3 further decreased the WNK4 protein level compared with the expression of KLHL3 alone. Cullin3 alone did not affect WNK4 abundance. These data suggested that the KLHL3-Cullin3 complex might be a strong regulator of the WNK4 protein abundance within cells. Although we tried to measure the half-life of WNK4 in the presence of KLHL3 and Cullin3, the robust decrease of WNK4 by KLHL3 and Cullin3 made the measurement extremely difficult. The difference could be highly significant based on the steady-state levels of transiently expressed WNK4, as shown in Figures 2A and 2B.

Next, we evaluated how a PHAII-causing mutation (R528H) of KLHL3 and Cullin3 affected the abundance of WNK4. When the expression levels of wild-type and mutant KLHL3 were similar, the R528H mutant was less able to reduce the endogenous protein level of WNK4 as compared to wild-type KLHL3 (Figure 2C). The PHAII-causing mutations of the *Cullin3* gene were reported to cause skipping of exon 9, which codes the segment (57 residues from 403–459) linking the BTB-binding and RING-binding domains of Cullin3 (Boyden et al., 2012). To investigate the pathogenic effect of the mutant Cullin3, we prepared Cullin3 lacking this segment. As shown in Figure 2E, the mutant Cullin3 was also less able to reduce WNK4 as compared to wild-type Cullin3.




Figure 2. Effect of Wild-Type and PHAI1-Causing Mutant KLHL3 and Cullin3 Expression on Cellular WNK4 Abundance
 (A) When coexpressed with KLHL3, the abundance of WNK4 protein within HEK293T cells expressed by CMV promoter (p3×FLAG-CMV-10 vector, Sigma-Aldrich) was dramatically decreased, whereas the abundance of BAP expressed by the same expression vector was not affected by KLHL3 coexpression.
 (B) The reduction of WNK4 by KLHL3 coexpression was confirmed in another expression system of WNK4 (pRK5 vector), and OSR1, SPAK, and NCC levels were not affected by KLHL3 coexpression. Results similar to those shown in (A) and (B) were obtained in three separate experiments.
 (C) Effect of wild-type and a PHAI1-causing mutant (R528H) KLHL3 expression on the cellular abundance of WNK4. Endogenous WNK4 level in mpkDCT cells was decreased by wild-type KLHL3 expression. However, a similar level of the mutant KLHL3 expression failed to reduce WNK4 (* $p < 0.05$, compared with the WNK4 levels without KLHL3 coexpression [left lane] and with the mutant KLHL3 coexpression [right lane]; $n = 3$; mean \pm SEM).
 (D) Effect of the endogenous KLHL3 knockdown in mpkDCT cells on WNK4 expression. The protein levels of WNK4 were higher in KLHL3-knocked-down cells than in control cells. siRNA, small interfering RNA.
 (E) Effect of wild-type and a PHAI1-causing mutant *Cullin3* expression on the cellular abundance of WNK4. Although the expression of Cullin3 alone did not affect WNK4 protein level, Cullin3 expression with KLHL3 dramatically reduced WNK4 protein. The mutant *Cullin3* lacking the portion corresponding to exon 9 was less able to reduce WNK4 protein. The existence of two bands in the immunoblot of Cullin3 was reported previously (McEvoy et al., 2007). Similar results were obtained in three separate experiments.

PHAI1-Causing Mutations of WNK4 and KLHL3 Affected the Interaction of WNK4 and KLHL3 and the Ubiquitination of WNK4

To investigate the mechanism(s) by which KLHL3 regulates the WNK4 protein level, we examined the ubiquitination of wild-type and PHAI1-causing WNK4 with or without wild-type and mutant KLHL3. In this assay, we did not overexpress Cullin3, but used endogenous Cullin3 in HEK 293T cells (Figure 1C) because the overexpression of Cullin3 with KLHL3 robustly decreased WNK4 protein abundance (Figure 2E) under our experimental conditions, even in the presence of proteasome inhibitors, which made it difficult to recover WNK4 for immunoprecipitation. After coexpression of FLAG-tagged WNK4, Halo-tagged KLHL3, and hemagglutinin (HA)-tagged ubiquitin in HEK293T cells, the cells were treated with 1 μ M epoxomicin,

and WNK4 was immunoprecipitated with FLAG antibody. First, we evaluated whether KLHL3 expression increased WNK4 ubiquitination. For the exclusion of ubiquitination signals from other proteins coimmunoprecipitated with WNK4, the immunoprecipitation was performed under a denaturing condition (Figure 3A). As previously shown in Figures 2A and 2B, when we expressed the wild-type KLHL3, the level of coexpressed wild-type WNK4 decreased significantly, even in the presence of a potent proteasome inhibitor (see WNK4 immunoblots of lysates and immunoprecipitated products in Figures 3A and 3C). As shown in the ubiquitin (HA) immunoblot (Figure 3A), the ubiquitination signals were observed as a smear band of over 200 kDa, which is the apparent molecular size of WNK4 (arrow). This data strongly suggested that WNK4 itself was indeed ubiquitinated, given that the immunoprecipitation was performed

under a denaturing condition. This ubiquitination was apparently increased by KLHL3 coexpression when the ubiquitination signals were corrected by the immunoprecipitated WNK4 abundance. To make the difference clear without correction, we adjusted the loading amount of the immunoprecipitated product to have the same amount of immunoprecipitated WNK4 in each lane in Figure 3A. A significant increase of WNK4 ubiquitination by KLHL3 was observed.

To further confirm that WNK4 was directly ubiquitinated by the KLHL3-Cullin3 complex, we performed an *in vitro* ubiquitination assay. Because the preparation of whole WNK4 protein was not successful, we prepared a portion of human WNK4 protein (residues from 490 to 626) containing the PHAII mutation sites as a GST fusion protein with a C-terminal His tag (50 kDa). As shown in the right panels of Figure 3A, we could confirm that the KLHL3-Cullin3 complex was able to directly ubiquitinate WNK4 (490–626).

Second, we tested the effect of the R528H KLHL3 mutation on WNK4 binding and ubiquitination. As already shown in Figure 2C, coexpression of wild-type KLHL3 significantly reduced WNK4 expression as compared with the mutant KLHL3 (Figure 3B, upper three panels). We observed a significant decrease in WNK4 ubiquitination by the mutant KLHL3 and also the decreased interaction of WNK4 with the mutant KLHL3 (Figure 3B, lower three panels).

We also tested the effect of PHAII-causing mutations of *WNK4* on WNK4-KLHL3 interaction and WNK4 ubiquitination. As shown in Figure 3A, wild-type KLHL3 decreased WNK4. However, this decrease mediated by KLHL3 was blunted in all three PHAII-causing *WNK4* mutants (Figure 3C, upper WNK4 panels). In the lower panels of Figure 3C, we showed the immunoblots of coimmunoprecipitated KLHL3 and ubiquitinated WNK4 after the loading adjustment as shown in Figures 3A and 3B. At the same time, we measured the signals before the loading adjustment and corrected the levels of WNK4 abundance as shown in Figure 3D. In either analysis, we could observe that the WNK4 mutants appeared to show less interaction with wild-type KLHL3 and less ubiquitination compared with wild-type WNK4. An *in vitro* ubiquitination assay using the wild-type and the mutant (D564A) WNK4 also supported this data (Figure S1).

The above data suggested that the acidic domain of WNK kinases (Figure 4), where PHAII mutants were clustered in WNK4, might be involved in the interaction with KLHL3. To investigate this hypothesis and to clarify whether the interaction of WNK4 and KLHL3 was direct, we measured the binding of TAMRA-labeled WNK4 peptide covering the acidic motif to the whole KLHL3 protein as a GST fusion protein *in vitro*. We used fluorescence correlation spectroscopy (FCS) to measure the diffusion time of the fluorescent peptide (FluoroPoint-Light, Olympus, Tokyo) (Kuroki et al., 2007), in the presence of different concentrations of GST-KLHL3. As shown in Figure 4, the diffusion time of TAMRA-labeled peptide became slower as the concentration of GST-KLHL3 increased, indicating that the WNK4 peptide bound to GST-KLHL3. GST alone did not affect the diffusion time, and the introduction of a PHAII-causing mutation (D564A) abolished the decrease in diffusion time by GST-KLHL3, clearly indicating that KLHL3 directly binds to WNK4.

WNK4 Protein Level Increased in the PHAII Model Mouse (*Wnk4*^{D561A/+}) Kidney

To determine whether the mechanism clarified in the cell culture studies was in fact working in the *in vivo* kidney, we re-evaluated our PHAII model mice carrying the D561A WNK4 mutation, which is equivalent to the human D564A mutation.

By using a recently generated WNK4 antibody that recognizes the amino terminus of WNK4 (Ohno et al., 2011), we found that the WNK4 protein level was significantly increased in the *Wnk4*^{D561A/+} mouse kidney (Figure 5A), which we missed in our initial report (Yang et al., 2007). The specificity of this WNK4 antibody was rigorously verified (Ohno et al., 2011) and also recently confirmed by using *WNK4* knockout mice (Figure S2). Furthermore, the *Wnk4*^{D561A/D561A} homozygous mouse showed a more increased WNK4 protein level, suggesting that the mutation may have a substantial effect in the regulation of the WNK4 protein level *in vivo*. We confirmed that the WNK4 messenger RNA (mRNA) level was not increased in the *Wnk4*^{D561A/D561A} homozygous mouse kidney (Figure 5B), indicating that the increase in the WNK4 protein level was not caused by transcriptional activation.

Increased Expression of WNK4 in the Kidney Induced the Activation of the WNK-OSR1/SPAK-NCC Signal Cascade

To confirm whether the increased WNK4 protein level activates OSR1/SPAK-NCC signaling in the kidney, we generated bacterial artificial chromosome (BAC)-transgenic (TG) mice harboring multiple copies of the wild-type *WNK4* gene, as previously reported (Lalioi et al., 2006). As shown in Figure 6A, we presented the results of two representative transgenic lines; one had a low copy number of the transgene (two copies) and the other had a high copy number (thirty copies). WNK4 protein levels in the kidneys of low copy number (LC) and high copy number (HC) TG mice were increased 1.7 ± 0.1 (mean ± SEM)-fold in LC-TG mice and 9.1 ± 0.2-fold in HC-TG mice (n = 5), compared with those of wild-type mice. The phosphorylation of OSR1, SPAK, and NCC in the kidney (Figure 6A) clearly increased as the WNK4 protein levels increased in the TG mice. Immunofluorescence of phosphorylated NCC and WNK4 also clearly showed the overexpression of WNK4 and the increased phosphorylation of NCC in the distal convoluted tubules (Figure S3), confirming the activation of WNK-OSR1/SPAK-NCC signaling in the TG mice. Nighttime systolic, diastolic, and mean blood pressure and daytime diastolic blood pressure were significantly increased as the WNK4 protein levels increased in the TG mice (Figure 6B). The blood pressure in these TG mice was also comparable to that of *Wnk4*^{D561A/+} knockin mice measured by the same telemetry system (wild-type versus *Wnk4*^{D561A/+} knockin: 118.3 ± 0.77 versus 125.1 ± 0.90, mean ± SEM, n = 4, p < 0.05). The LC-TG and HC-TG mice also showed hyperkalemia and metabolic acidosis (Table 1) like *Wnk4*^{D561A/+} knockin mice, and these phenotypes were more severe in HC-TG than LC-TG mice. We also investigated the phosphorylation status of NCC in two additional lines of transgene: one with no increase in WNK4 protein with two copies of the transgene, suggesting that the copy number of the transgene did not assure overexpression of the gene product, and the other with a robust




Figure 3. Effect of KLHL3 on the Ubiquitination of Wild-Type and PHAII-Causing Mutant WNK4

(A) Left panels: KLHL3 coexpression significantly induced the ubiquitination of wild-type WNK4. WNK4 was immunoprecipitated under a denaturing condition, and ubiquitinated WNK4 was observed as a smear band over 200 kDa, which is the apparent molecular size of WNK4 (arrow). Coexpression of wild-type KLHL3 significantly reduced the wild-type WNK4 level, even in the presence of 1 μ M epoxomicin. Accordingly, in the lower panels, we reloaded the immunoprecipitated WNK4 samples to have equal amounts of immunoprecipitated WNK4 in each lane to demonstrate the difference in ubiquitination in each lane more clearly. We confirmed in the preliminary experiments that the data after loading adjustment faithfully reflected the data corrected by the immunoprecipitated WNK4 abundance before adjustment.

Right panels: In vitro ubiquitination assay of WNK4. WNK4 (490–626; 50 kDa) was incubated with ubiquitin, E1, and E2 (UbcH5a/UBE2D1) with or without the Cullin3-KLHL3 complex. Cullin3-KLHL3 significantly ubiquitinated WNK4 (490–626) in vitro. Similar results were obtained in three separate experiments.

(legend continued on next page)




Figure 4. Direct Binding of KLHL3 to the Acidic Motif of Wild-Type WNK4

The diffusion time of a single-molecule TAMRA-labeled peptide corresponding to the acidic domain of wild-type WNK4 was measured by FCS. The addition of GST-KLHL3, not of GST only, dose-dependently increased the diffusion time, indicating the direct binding of KLHL3 to the acidic domain of WNK4 ($K_d = 0.20 \mu\text{M}$). The diffusion time of a TAMRA-labeled peptide carrying a PHAI1-causing mutation (D564A) was not affected by the addition of GST-KLHL3. The results are presented as means \pm SEM ($n = 5$). N.D., not determined.

increase in WNK4 protein with twenty copies of the transgene. The increased phosphorylation of NCC was only observed in the line with WNK4 overexpression (Figure S4). These results clearly indicate that the activation of the WNK-OSR1/SPAK-NCC cascade and the induction of PHAI1 phenotypes were dependent on the increased WNK4 protein levels in the in vivo kidney.

(B) Effect of wild-type and a PHAI1-causing mutant KLHL3 expression on WNK4-KLHL3 binding and WNK4 ubiquitination. Upper panels: as shown in Figure 2C, wild-type KLHL3 reduced the coexpressed WNK4 protein level more significantly than did the mutant KLHL3, even in the presence of $1 \mu\text{M}$ epoxomicin. Accordingly, as in Figure 3A, the immunoprecipitated WNK4 samples were reloaded for equal amounts of immunoprecipitated WNK4 in each lane (lower panels). The binding of WNK4 to mutant KLHL3 and WNK4 ubiquitination by the mutant KLHL3 were significantly impaired. The immunoprecipitation was performed under a nondenaturing condition for assessing the binding to KLHL3 in the same experiments. Similar results were obtained in three separate experiments.

(C) Effect of PHAI1-causing mutations of WNK4 on WNK4-KLHL3 binding and WNK4 ubiquitination. As shown in Figure 3A, coexpression of wild-type KLHL3 significantly reduced the wild-type WNK4 level, even in the presence of $1 \mu\text{M}$ epoxomicin. However, this decrease was blunted in PHAI1-causing WNK4 mutations (see WNK4 immunoblots of lysates or immunoprecipitates in the upper panels). All three PHAI1-causing WNK4 mutants showed less ubiquitination and less binding to KLHL3 (see quantification of blots in D).

(D) Quantification of the results showing the comparison of WNK4 ubiquitination and WNK4 binding to KLHL3 among wild-type and PHAI1-causing WNK4 mutants. Upper graph, immunoprecipitated WNK4 abundance; middle graph, coimmunoprecipitated KLHL3 corrected by WNK4 abundance; lower graph, WNK4 ubiquitination corrected by WNK4 abundance. WNK4 ubiquitination was evaluated by separate sets of immunoprecipitation experiments under a denaturing condition. Data before loading adjustment were used for quantification. ($\#p < 0.05$ compared with wild-type [WT]-WNK4 without KLHL3; $*p < 0.05$ compared with WT-WNK4 with KLHL3; $n = 3$; mean \pm SEM).

See also Figure S1.




Figure 5. Increased WNK4 Protein Levels in *Wnk4*^{D561A/+} and *Wnk4*^{D561A/D561A} Knockin Mice

(A) WNK4 in *Wnk4*^{D561A/+} and *Wnk4*^{D561A/D561A} mice was increased 2.2 ± 0.1 - and 2.7 ± 0.2 -fold, respectively, compared with that in wild-type mice ($n = 6$, mean \pm SEM).

(B) WNK4 transcription was not increased in the *Wnk4*^{D561A/D561A} PHAI1 model mouse. Quantitative RT-PCR revealed that WNK4 mRNA levels in *Wnk4*^{+/+} (open bar) and *Wnk4*^{D561A/D561A} (closed bar) mouse kidneys were not statistically different (mean \pm SEM; $n = 6$; $p = 0.34$). n.s., not significant. See also Figure S2.

DISCUSSION

We previously demonstrated the activation of the WNK-OSR1/SPAK-NCC phosphorylation cascade in the mouse model of PHAI1, *Wnk4*^{D561A/+} knockin mice (Yang et al., 2007), by developing phosphospecific antibodies for residues of the amino-terminal domain of NCC (Chiga et al., 2008; Yang et al., 2007). Then, we and others clarified that this signal cascade was important in blood pressure regulation under certain pathophysiological conditions other than PHAI1 (Hoorn et al., 2011; Komers et al., 2012; San-Cristobal et al., 2009; Sohara et al., 2011). Thus, there is wide agreement (Gamba, 2012) that the phosphorylation status of NCC governed by WNK-OSR1/SPAK signaling reflects NCC activity in vivo. Given that PHAI1 is a thiazide-sensitive disease, we speculated that *KLHL3* and *Cullin3* mutations




Figure 6. Generation and Analysis of *WNK4* TG Mice
(A) Status of the WNK-OSR1/SPAK-NCC phosphorylation cascade in the *WNK4* TG mice ($Tg(Wnk4^{WT})$). WNK4 protein levels in the kidneys of LC (two copies) and HC (thirty copies) TG mice were increased 1.7 ± 0.1 - and 9.1 ± 0.2 -fold, respectively (* $p < 0.05$, $n = 5$, mean \pm SEM). NCC phosphorylation in these mice was significantly increased, compared with that of wild-type mice ($p < 0.05$, $n = 5$, mean \pm SEM). The phosphorylation of SPAK in LC-TG and HC-TG mice and that of OSR1 in HC-TG mice was also significantly increased compared to that of wild-type mice ($p < 0.05$, $n = 5$, mean \pm SEM). The total and phosphorylated OSR1, SPAK, and NCC in HC-TG mice were significantly increased compared with those in LC-TG mice ($p < 0.05$, $n = 5$, mean \pm SEM). (B) Nighttime systolic, diastolic, and mean blood pressure (BP) and daytime diastolic blood pressure were significantly increased as the WNK4 protein levels increased in the $Tg(Wnk4^{WT})$ mice. Values were collected over 7 consecutive days (daytime: from 8:00 until 20:00; nighttime: from 20:00 until 8:00). * $p < 0.05$ versus WT; † $p < 0.05$ versus LC; WT $n = 5$; LC-TG $n = 5$; HC-TG $n = 4$; mean \pm SEM. See also Figures S3 and S4.

would also activate the WNK-OSR1/SPAK-NCC phosphorylation cascade. Gamba's group also recently clarified that the major WNK kinase regulating NCC phosphorylation in the kidney

Table 1. Blood Biochemistries of WT and LC- and HC- $Tg(Wnk4^{WT})$ Mice

	WT Mice ($n = 16$)	LC ($n = 16$) $Tg(Wnk4^{WT})$ Mice	HC ($n = 16$) $Tg(Wnk4^{WT})$ Mice
Na (mmol/l)	145.4 ± 0.3	$147.0 \pm 0.3^*$	$147.4 \pm 0.5^{**}$
K (mmol/l)	4.2 ± 0.1	$5.1 \pm 0.1^{**}$	$5.5 \pm 0.1^{**,\dagger}$
Cl (mmol/l)	110.3 ± 0.3	$111.9 \pm 0.3^{**}$	$112.8 \pm 0.5^{**}$
HCO ₃ ⁻ (mmol/l)	24.4 ± 0.3	$21.5 \pm 0.4^{**}$	$21.1 \pm 0.3^{**}$
pH (venous)	7.302 ± 0.023	$7.245 \pm 0.003^{**}$	$7.220 \pm 0.004^{**,\ddagger}$

Values are the mean \pm SEM. *, $p < 0.05$; **, $p < 0.01$ versus wild-type (WT) (one-way ANOVA followed by Tukey's post hoc test). †, $p < 0.05$; ‡, $p < 0.01$ versus low copy number (one-way ANOVA followed by Tukey's test). Low copy number (LC) and high copy number (HC) $Tg(Wnk4^{WT})$ mice showed hyperkalemia and metabolic acidosis.

is WNK4 (Castañeda-Bueno et al., 2012). Accordingly, we first performed coimmunoprecipitation assays of KLHL3 with the components of the WNK4-OSR1/SPAK-NCC cascade because KLHL proteins have been recently identified as substrate adaptors in the Cullin3-based ubiquitin E3 ligase (Cirak et al., 2010; Kigoshi et al., 2011; Lee et al., 2010; Lin et al., 2011).

We found that KLHL3 showed a clear interaction only with WNK4 among the components of the cascade. The direct binding of WNK4 to KLHL3 at the acidic motif was also confirmed in this study. In addition to the interaction, we showed that KLHL3 coexpression dramatically reduced both overexpressed and endogenous WNK4, indicating that KLHL3 is a strong regulator of WNK4 protein abundance within cells. Such an effect was reduced in the PHAII-causing mutations of WNK4 and KLHL3, resulting in a common consequence: the increase in WNK4 protein abundance. We also confirmed that the interaction of KLHL3 with WNK4 induced the ubiquitination of WNK4 in HEK293T cells and in *in vitro* ubiquitination assay. The reduced interaction of KLHL3 with WNK4 by PHAII-causing mutations in either protein also reduced the ubiquitination of WNK4, and the PHAII-causing mutant *Cullin3* was less able to reduce WNK4 protein abundance. Although we cannot exclude the possibility that KLHL3 may have targets other than WNK4, these results strongly suggest that WNK4 protein abundance within cells is regulated by KLHL3-Cullin3-mediated ubiquitination of WNK4 and that the major common molecular mechanism of PHAII is the impaired ubiquitination of WNK4.

Because the *in vitro* data could explain the molecular pathogenesis of PHAII caused by three different kinds of molecules, i.e., WNK4, KLHL3, and Cullin3, we verified this idea *in vivo*. Previously, WNK4 was shown to be able to phosphorylate and activate OSR1 and SPAK, as well as WNK1, *in vitro* (Moriguchi et al., 2005), and Ahlstrom and Yu (2009) reported in HEK293 cells that the intrinsic kinase activity of PHAII-causing mutant WNK4 was not different from that of wild-type WNK4. Given that the recent data on *WNK4* knockout mice (Castañeda-Bueno et al., 2012) clearly indicate that WNK4 is the major WNK kinase in the kidney, we think it is reasonable to infer that the increased WNK4 abundance in the kidney, as we observed in the *Wnk4*^{D561A/+} mice, could activate the cascade and was the cause of PHAII. To further prove this idea, we generated wild-

type *WNK4*-TG mice as previously reported (Lalioi et al., 2006). We evaluated several lines of TG mice with different levels of *WNK4* protein overexpression, and we think that *WNK4* TG mice could mimic *Wnk4*^{D561A/+} knockin mice. We clearly showed that the WNK-OSR1/SPAK-NCC cascade and the PHAI1 phenotypes were induced according to the increases in wild-type *WNK4* protein overexpression. This *WNK4*-dependent ubiquitination of *WNK4* is a common mechanism of PHAI1 by expression of phenotypes strongly suggests that these phenotypes were not caused by a nonspecific effect of the transgene. Several studies, mainly performed in *Xenopus* oocytes and in cultured cells, have shown that *WNK4* behaves as a negative regulator of NCC (Wilson et al., 2003; Yang et al., 2003). This negative effect was shown to be a kinase-activity-independent function of *WNK4* (Yang et al., 2005), suggesting that the kinase-activity-dependent positive and -activity-independent negative effects of *WNK4* might act on NCC concomitantly and that the net effect might differ in different experimental situations. In fact, the *WNK4*-TG mouse with the wild-type *WNK4* gene generated by Lalioi et al. (2006) was reported to show Gitelman-syndrome-like phenotypes rather than those of PHAI1, which is contrary to our TG data in this study. No data regarding the status of the WNK-OSR1/SPAK-NCC cascade and *WNK4* protein level in their TG mice have been reported (Lalioi et al., 2006). In addition, it was not clear whether the negative effect of wild-type *WNK4* on NCC was dependent on *WNK4* protein levels, because only a single line of TG mice was reported. Therefore, the reason for the discrepancy between our *WNK4* TG study and Lalioi's study is not clear. It is possible that the level of *WNK4* protein in their TG mice might be less than those in our *WNK4* TG mice and PHAI1 models (about 2-fold increases); they mentioned that only a 50% increase in *WNK4* mRNA expression was observed in their TG mice. The net effect of *WNK4* on NCC might be expressed as a negative effect under such conditions. Our previous study using the triple knockin mice of *WNK4*, *OSR1*, and *SPAK* suggested that the contribution of this negative effect of *WNK4* on NCC might be minimal in the kidney, at least under PHAI1 conditions (Chiga et al., 2011). Our TG data in this study also clearly indicate that the increase in *WNK4* protein at the PHAI1 level or higher brought about a positive net effect on NCC.

Because NCC phosphorylation in the kidney is highly dependent on *WNK4* (Castañeda-Bueno et al., 2012; Oi et al., 2012; Susa et al., 2012), we focused on *WNK4* in this study. However, WNK kinases other than *WNK4* may also be regulated by the KLHL3-Cullin3 complex. The amino acid sequence of the KLHL3 binding site in *WNK4* is highly conserved in other WNK kinases (Figure 4), and we could observe that *WNK1* protein, as well as *WNK4* protein, was decreased by overexpression and increased by knockdown of KLHL3 (Figure S5). In this respect, *WNK1* as well as *WNK4* may be increased in the kidneys of patients with PHAI1 carrying the *KLHL3* and *Cullin3* mutations, thereby contributing to the activation of OSR1/SPAK-NCC signaling and to more severe PHAI1 phenotypes via Cullin3 and KLHL3 than those via *WNK1* and *WNK4* (Boyden et al., 2012). Because the PHAI1-causing mutations of *WNK1* are the large deletions of intron 1, which reportedly increases *WNK1* transcription (Wilson et al., 2001), the mechanism clarified in this study may not be directly related to the pathogenesis of PHAI1

by the *WNK1* mutations. However, we may consider PHAI1 as a disease caused by increased WNK kinase abundance either by the dysregulation of transcription or by the ubiquitination of WNK kinases.

In summary, our study identified that *WNK4* is a substrate of KLHL3-Cullin3-mediated ubiquitination and that the impaired ubiquitination of *WNK4* is a common mechanism of PHAI1 by *WNK4*, *KLHL3*, and *Cullin3* PHAI1-causing mutations. Additional studies may be necessary to confirm this pathogenic mechanism in vivo by generating *KLHL3* and *Cullin3* knockin mice carrying PHAI1 mutations.

EXPERIMENTAL PROCEDURES

Plasmids

Expression plasmids for 3×FLAG-tagged human *WNK4* and 3×FLAG-tagged D564A human *WNK4* have been described previously (Yamauchi et al., 2004). E562K and Q565E mutations were also introduced by using a QuikChange Site-Directed Mutagenesis Kit (Stratagene). The complementary DNA (cDNA) encoding Halo-tagged human KLHL3 in pFN21A vector (HT-KLHL3) was purchased from Promega, and a disease-causing mutation (R528H) was introduced. Human Cullin3 cDNA was isolated by RT-PCR using human prostate mRNA as a template, and the cDNA was cloned into 3×FLAG-CMV10 vector (Sigma-Aldrich). T7-tagged OSR1, T7-tagged SPAK, and T7-tagged NCC expression plasmids in pRK5 vector were kindly provided by T. Moriguchi and H. Shibuya (Moriguchi et al., 2005). T7-tagged human *WNK4* construct was also generated by introducing the T7 epitope by PCR. HA₄-tagged ubiquitin expression vector was kindly provided by T. Ohta (St. Marianna University School of Medicine).

Cell Culture and Transfections

HEK293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin at 37°C in a humidified 5% CO₂ incubator. The mpkDCT cell line kindly provided by A. Vandewalle was cultured in a defined medium as described previously (Duong Van Huyen et al., 2001). HEK293T cells and mpkDCT cells (3 × 10⁵ cells per 6 cm dish) were transfected by the indicated amount of plasmid DNA with Lipofectamine 2000 reagent (Invitrogen). For each transfection, 4–8 μg of expression vectors were used, and the total amount of plasmid DNA was adjusted by adding empty vectors. In preliminary experiments, FLAG-tagged BAP (Figure 2A) was used for evaluating the transfection efficiency of transient expression of FLAG-tagged *WNK4*.

Immunoprecipitation

HEK293T cells transfected with the indicated amount of DNA were lysed in a buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 1 mM sodium orthovanadate, 50 mM sodium fluoride, and protease inhibitor cocktail) for 30 min at 4°C. When the cells were transfected with the HA-ubiquitin expression plasmid, the cells were treated with 1 μM epoxomicin (specific and irreversible proteasome inhibitor; Peptide Institute, Osaka, Japan) for 3 hr before harvesting. After centrifugation at 12,000 × g for 15 min, the protein concentration of the supernatants was measured, and equal amounts of the supernatants were used for immunoprecipitation with anti-FLAG M2 beads (Sigma-Aldrich) or anti-T7 beads (Merck Millipore) for 2 hr at 4°C. Thereafter, the precipitants were washed with the lysis buffer and the immunoprecipitates were eluted in SDS sample buffer after boiling for 5 min. To detect ubiquitination of *WNK4* in denatured samples, the cells transfected with various plasmids were lysed in 2% SDS buffer (2% SDS, 150 mM NaCl, 10 mM Tris-HCl [pH 8.0], 2 mM sodium orthovanadate, 50 mM sodium fluoride, and 1× protease inhibitors) and boiled for 10 min, followed by sonication. Before immunoprecipitation, the lysates were diluted 1:10 in a dilution buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 2 mM EDTA, and 1% Triton X-100), incubated at 4°C for 1 hr with rotation, and centrifuged at 12,000 × g for 15 min.

Immunoblotting

Whole homogenates of mouse kidney without the nuclear fraction (600 × *g*) or the crude membrane fraction (17,000 × *g*) were subjected to semiquantitative immunoblotting, as described previously (Yang et al., 2007). Cells transfected with the indicated amount of plasmid DNA were lysed in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 1 mM sodium orthovanadate, 50 mM sodium fluoride, and protease inhibitor cocktail [Roche Diagnostics]) for 30 min at 4°C. After centrifugation at 12,000 × *g* for 15 min, the supernatants were boiled with SDS sample buffer (Cosmo Bio USA) and subjected to SDS-PAGE. Blots were probed with the following primary antibodies: anti-total NCC (Ohno et al., 2011), anti-phosphorylated NCC (pSer71) (Yang et al., 2007), anti-WNK4 (Ohno et al., 2011; Ohta et al., 2009), anti-total OSR1 (M9; Abnova), anti-phosphorylated OSR1 (Ohta et al., 2009), anti-total SPAK (Cell Signaling Technology), anti-phosphorylated SPAK (Yang et al., 2010), anti-GAPDH (Santa Cruz Biotechnology), anti-actin (Cytoskeleton), anti-HA (Merck Millipore), anti-KLHL3 (Abcam), anti-Cullin3 (Abcam), anti-FLAG (Sigma-Aldrich), anti-Halo (Promega), and anti-T7 (Merck Millipore). Specificities of anti-pNCC, pOSR1, and pSPAK were rigorously determined in our previous reports (Chiga et al., 2008; Ohta et al., 2009; Yang et al., 2007, 2010). Alkaline-phosphatase-conjugated immunoglobulin G antibodies (Promega) were used as secondary antibodies for immunoblotting. The intensity of the bands was analyzed and quantified by using ImageJ software (National Institutes of Health).

In Vitro Ubiquitination Assay

cDNA encoding human WNK4 (490–626) with a C-terminal His-tag was amplified by PCR and cloned into pGEX6p-1 vector. Recombinant GST fusion WNK4 protein was expressed in BL21 *E. coli* cells and purified by using glutathione sepharose beads. KLHL3-Cullin3 complexes were immunoprecipitated from the lysates of HEK293T cells transiently expressing FLAG-Cullin3 and Halo-KLHL3. Then, the complexes were incubated in 20 μl of reaction buffer (50 mM Tris-HCl [pH 7.4], 2.5 mM MgCl₂, 0.5 mM DTT, and 2 mM ATP) for 2 hr at 30°C with purified GST-WNK4-His (5 μg), 100 ng recombinant human E1 (Boston Biochem), 500 ng recombinant human UbcH5a/UBE2D1 (Boston Biochem), and 2.5 μg recombinant human ubiquitin (Boston Biochem). The reaction was terminated by the addition of SDS-PAGE sample buffer, followed by boiling for 5 min. The reaction mixtures were then subjected to immunoblot analyses with ubiquitin (Cell Signaling Technology) or His (Abcam) antibodies.

Quantitative RT-PCR

6.1441mmBoth kidneys were removed, immediately frozen in dry ice, and fragmented and homogenized in TRIzol Reagent (Invitrogen). Isolated total RNA was reverse-transcribed by using Omniscript reverse transcriptase (QIAGEN), and quantitative real-time PCR analysis was performed in triplicate by using SYBR Green I (Roche Applied Science) on LightCycler 2.0 (Roche). Amplification primers for *WNK4* were the same as reported previously (O'Reilly et al., 2006), and the primers for *GAPDH* were purchased from Roche Diagnostics. *WNK4* mRNA levels were corrected by *GAPDH* mRNA levels.

Fluorescence Correlation Spectroscopy

Fluorescent TAMRA-labeled WNK4 peptides covering the PHAI1 mutation sites were prepared (Hokkaido System Science, Hokkaido, Japan). The sequence details of the peptides are shown in Figure 4. Human full-length KLHL3 was cloned into pGEX6P-1 vector. Recombinant GST fusion KLHL3 protein was expressed in BL21 *E. coli* cells and purified by using glutathione sepharose beads. The TAMRA-labeled WNK4 peptides were incubated at room temperature for 30 min with different concentrations of GST-KLHL3 (0–2 μM) in 1 × PBS with 0.05% Tween 20 reaction buffer, and the FCS measurements of single-molecule fluorescence were performed using the FluoroPoint-Light analytical system (Olympus) (Kuroki et al., 2007). The assay was performed in a 384-well plate. All experiments were performed in 10 s of data-acquisition time, and the measurements were repeated five times per sample.

Production of *Wnk4* BAC TG Mice

The BAC clone bMQ428o09, which contains the mouse genomic *Wnk4* locus, was used. For Southern blot analysis and PCR genotyping, a new *SpeI* site was created in intron 6 of the *Wnk4* genomic locus. The BAC modification was performed as previously described (Warming et al., 2005). Purified BAC DNA was then digested with *Swal*, and the desired 36.8 kb fragment was isolated after fractionation via inverted pulse field gel electrophoresis, as reported previously (Lalioti et al., 2006). The purified fragment was injected into one-cell embryos of C57BL/6J mice. The copy number of the transgene was estimated by Southern blotting and quantitative PCR. The Animal Care and Use Committee of Tokyo Medical and Dental University approved this experiment (0120038B).

Blood Pressure Measurements

We measured blood pressure by using a radiotelemetric method (Mills et al., 2000) in which a blood pressure transducer (Data Sciences International, St. Paul, MN, USA) was inserted into the left carotid artery. Seven days after transplantation, each mouse was housed individually in a standard cage on a receiver under a 12 hr light-dark cycle. Systolic and diastolic blood pressure, heart rate, and activity were recorded every minute via radiotelemetry. Mice showed alternating periods of high activity (20:00–8:00) and low activity (8:00–20:00). For each mouse, we measured blood pressure values for more than 5 consecutive days and calculated the mean ± SEM of all values during both the high- and low-activity periods.

Blood Data Analyses

Blood for electrolyte analyses was obtained as described previously (Yang et al., 2007). Electrolyte levels were determined with an i-STAT analyzer (Fuso Pharmaceutical Industries, Osaka, Japan).

Statistical Analysis

Comparisons between the two groups were performed with unpaired *t* tests. ANOVA with Tukey's post hoc test was used to evaluate statistical significance in the comparison among multiple groups. *p* values <0.05 were considered statistically significant. Data are presented as the mean ± SEM.

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2013.02.024>.

LICENSING INFORMATION

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

ACKNOWLEDGMENTS

This study was supported in part by Grants-in-Aid for Scientific Research (A) from the Japan Society for the Promotion of Science; a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare; the Salt Science Research Foundation (grant no. 1026, 1228); the Takeda Science Foundation; and a Banyu Foundation Research Grant.

Received: November 28, 2012

Revised: January 25, 2013

Accepted: February 13, 2013

Published: February 28, 2013

REFERENCES

Achard, J.M., Disse-Nicodeme, S., Fiquet-Kempf, B., and Jeunemaitre, X. (2001). Phenotypic and genetic heterogeneity of familial hyperkalaemic hypertension (Gordon syndrome). *Clin. Exp. Pharmacol. Physiol.* 28, 1048–1052.

- Ahlstrom, R., and Yu, A.S. (2009). Characterization of the kinase activity of a WNK4 protein complex. *Am. J. Physiol. Renal Physiol.* 297, F685–F692.
- Bergaya, S., Faure, S., Baudrie, V., Rio, M., Escoubet, B., Bonnin, P., Henrion, D., Loirand, G., Achard, J.M., Jeunemaitre, X., and Hadchouel, J. (2011). WNK1 regulates vasoconstriction and blood pressure response to α 1-adrenergic stimulation in mice. *Hypertension* 58, 439–445.
- Boyden, L.M., Choi, M., Choate, K.A., Nelson-Williams, C.J., Farhi, A., Toka, H.R., Tikhonova, I.R., Bjornson, R., Mane, S.M., Colussi, G., et al. (2012). Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. *Nature* 482, 98–102.
- Castañeda-Bueno, M., Cervantes-Pérez, L.G., Vázquez, N., Uribe, N., Kantesaria, S., Morla, L., Bobadilla, N.A., Doucet, A., Alessi, D.R., and Gamba, G. (2012). Activation of the renal Na⁺/Cl⁻ cotransporter by angiotensin II is a WNK4-dependent process. *Proc. Natl. Acad. Sci. USA* 109, 7929–7934.
- Chiga, M., Rai, T., Yang, S.S., Ohta, A., Takizawa, T., Sasaki, S., and Uchida, S. (2008). Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. *Kidney Int.* 74, 1403–1409.
- Chiga, M., Rafiqi, F.H., Alessi, D.R., Sohara, E., Ohta, A., Rai, T., Sasaki, S., and Uchida, S. (2011). Phenotypes of pseudohypoaldosteronism type II caused by the WNK4 D561A missense mutation are dependent on the WNK-OSR1/SPAK kinase cascade. *J. Cell Sci.* 124, 1391–1395.
- Cirak, S., von Deimling, F., Sachdev, S., Errington, W.J., Herrmann, R., Bönne-mann, C., Brockmann, K., Hinderlich, S., Lindner, T.H., Steinbrecher, A., et al. (2010). Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. *Brain* 133, 2123–2135.
- Duong Van Huyen, J.P., Bens, M., Teulon, J., and Vandewalle, A. (2001). Vasopressin-stimulated chloride transport in transimmortalized mouse cell lines derived from the distal convoluted tubule and cortical and inner medullary collecting ducts. *Nephrol. Dial. Transplant.* 16, 238–245.
- Gamba, G. (2012). Regulation of the renal Na⁺/Cl⁻ cotransporter by phosphorylation and ubiquitylation. *Am. J. Physiol. Renal Physiol.* 303, F1573–F1583.
- Gordon, R.D. (1986). Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. *Hypertension* 8, 93–102.
- Hoorn, E.J., Walsh, S.B., McCormick, J.A., Fürstenberg, A., Yang, C.L., Roeschel, T., Paliege, A., Howie, A.J., Conley, J., Bachmann, S., et al. (2011). The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. *Nat. Med.* 17, 1304–1309.
- Kigoshi, Y., Tsuruta, F., and Chiba, T. (2011). Ubiquitin ligase activity of Cul3-KLHL7 protein is attenuated by autosomal dominant retinitis pigmentosa causative mutation. *J. Biol. Chem.* 286, 33613–33621.
- Komers, R., Rogers, S., Oyama, T.T., Xu, B., Yang, C.L., McCormick, J., and Ellison, D.H. (2012). Enhanced phosphorylation of Na⁺/Cl⁻ co-transporter in experimental metabolic syndrome: role of insulin. *Clin. Sci.* 123, 635–647.
- Kuroki, K., Kobayashi, S., Shiroishi, M., Kajikawa, M., Okamoto, N., Kohda, D., and Maenaka, K. (2007). Detection of weak ligand interactions of leukocyte Ig-like receptor B1 by fluorescence correlation spectroscopy. *J. Immunol. Methods* 320, 172–176.
- Lalioti, M.D., Zhang, J., Volkman, H.M., Kahle, K.T., Hoffmann, K.E., Toka, H.R., Nelson-Williams, C., Ellison, D.H., Flavell, R., Booth, C.J., et al. (2006). Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. *Nat. Genet.* 38, 1124–1132.
- Lee, Y.R., Yuan, W.C., Ho, H.C., Chen, C.H., Shih, H.M., and Chen, R.H. (2010). The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. *EMBO J.* 29, 1748–1761.
- Lin, M.Y., Lin, Y.M., Kao, T.C., Chuang, H.H., and Chen, R.H. (2011). PDZ-RhoGEF ubiquitination by Cullin3-KLHL20 controls neurotrophin-induced neurite outgrowth. *J. Cell Biol.* 193, 985–994.
- Liu, Z., Xie, J., Wu, T., Truong, T., Auchus, R.J., and Huang, C.L. (2011). Down-regulation of NCC and NKCC2 cotransporters by kidney-specific WNK1 revealed by gene disruption and transgenic mouse models. *Hum. Mol. Genet.* 20, 855–866.
- Louis-Dit-Picard, H., Barc, J., Trujillano, D., Miserey-Lenkei, S., Bouatia-Naji, N., Pylypenko, O., Beaurain, G., Bonnefond, A., Sand, O., Simian, C., et al.; International Consortium for Blood Pressure (ICBP). (2012). KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. *Nat. Genet.* 44, 456–460, S1–S3.
- McCormick, J.A., and Ellison, D.H. (2011). The WNKs: atypical protein kinases with pleiotropic actions. *Physiol. Rev.* 91, 177–219.
- McEvoy, J.D., Kossatz, U., Malek, N., and Singer, J.D. (2007). Constitutive turnover of cyclin E by Cul3 maintains quiescence. *Mol. Cell. Biol.* 27, 3651–3666.
- Mills, P.A., Huetteman, D.A., Brockway, B.P., Zwiers, L.M., Gelsema, A.J., Schwartz, R.S., and Kramer, K. (2000). A new method for measurement of blood pressure, heart rate, and activity in the mouse by radiotelemetry. *J. Appl. Physiol.* 88, 1537–1544.
- Moriguchi, T., Urushiyama, S., Hisamoto, N., Iemura, S., Uchida, S., Natsume, T., Matsumoto, K., and Shibuya, H. (2005). WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1. *J. Biol. Chem.* 280, 42685–42693.
- O'Reilly, M., Marshall, E., Macgillivray, T., Mittal, M., Xue, W., Kenyon, C.J., and Brown, R.W. (2006). Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo. *J. Am. Soc. Nephrol.* 17, 2402–2413.
- Ohno, M., Uchida, K., Ohashi, T., Nitta, K., Ohta, A., Chiga, M., Sasaki, S., and Uchida, S. (2011). Immunolocalization of WNK4 in mouse kidney. *Histochem. Cell Biol.* 136, 25–35.
- Ohta, A., Rai, T., Yui, N., Chiga, M., Yang, S.S., Lin, S.H., Sohara, E., Sasaki, S., and Uchida, S. (2009). Targeted disruption of the Wnk4 gene decreases phosphorylation of Na-Cl cotransporter, increases Na excretion and lowers blood pressure. *Hum. Mol. Genet.* 18, 3978–3986.
- Oi, K., Sohara, E., Rai, T., Misawa, M., Chiga, M., Alessi, D.R., Sasaki, S., and Uchida, S. (2012). A minor role of WNK3 in regulating phosphorylation of renal NKCC2 and NCC co-transporters in vivo. *Biol. Open* 1, 120–127.
- Rossier, B.C., and Schild, L. (2008). Epithelial sodium channel: mendelian versus essential hypertension. *Hypertension* 52, 595–600.
- San-Cristobal, P., Pacheco-Alvarez, D., Richardson, C., Ring, A.M., Vazquez, N., Rafiqi, F.H., Chari, D., Kahle, K.T., Leng, Q., Bobadilla, N.A., et al. (2009). Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. *Proc. Natl. Acad. Sci. USA* 106, 4384–4389.
- Shimkets, R.A., Warnock, D.G., Bositis, C.M., Nelson-Williams, C., Hansson, J.H., Schambelan, M., Gill, J.R., Jr., Ulick, S., Milora, R.V., Findling, J.W., et al. (1994). Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. *Cell* 79, 407–414.
- Sohara, E., Rai, T., Yang, S.S., Ohta, A., Naito, S., Chiga, M., Nomura, N., Lin, S.H., Vandewalle, A., Ohta, E., et al. (2011). Acute insulin stimulation induces phosphorylation of the Na-Cl cotransporter in cultured distal mpkDCT cells and mouse kidney. *PLoS ONE* 6, e24277.
- Susa, K., Kita, S., Iwamoto, T., Yang, S.S., Lin, S.H., Ohta, A., Sohara, E., Rai, T., Sasaki, S., Alessi, D.R., and Uchida, S. (2012). Effect of heterozygous deletion of WNK1 on the WNK-OSR1/SPAK-NCC/NKCC1/NKCC2 signal cascade in the kidney and blood vessels. *Clin. Exp. Nephrol.* 16, 530–538.
- Warming, S., Costantino, N., Court, D.L., Jenkins, N.A., and Copeland, N.G. (2005). Simple and highly efficient BAC recombineering using galK selection. *Nucleic Acids Res.* 33, e36.
- Wilson, F.H., Disse-Nicodème, S., Choate, K.A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D.V., Lipkin, G.W., Achard, J.M., et al. (2001). Human hypertension caused by mutations in WNK kinases. *Science* 293, 1107–1112.
- Wilson, F.H., Kahle, K.T., Sabath, E., Lalioti, M.D., Rapson, A.K., Hoover, R.S., Hebert, S.C., Gamba, G., and Lifton, R.P. (2003). Molecular

pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. *Proc. Natl. Acad. Sci. USA* *100*, 680–684.

Yamauchi, K., Rai, T., Kobayashi, K., Sohara, E., Suzuki, T., Itoh, T., Suda, S., Hayama, A., Sasaki, S., and Uchida, S. (2004). Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. *Proc. Natl. Acad. Sci. USA* *101*, 4690–4694.

Yang, C.L., Angell, J., Mitchell, R., and Ellison, D.H. (2003). WNK kinases regulate thiazide-sensitive Na-Cl cotransport. *J. Clin. Invest.* *111*, 1039–1045.

Yang, C.L., Zhu, X., Wang, Z., Subramanya, A.R., and Ellison, D.H. (2005). Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport. *J. Clin. Invest.* *115*, 1379–1387.

Yang, S.S., Morimoto, T., Rai, T., Chiga, M., Sohara, E., Ohno, M., Uchida, K., Lin, S.H., Moriguchi, T., Shibuya, H., et al. (2007). Molecular pathogenesis of pseudohypoaldosteronism type II: generation and analysis of a Wnk4(D561A/+) knockin mouse model. *Cell Metab.* *5*, 331–344.

Yang, S.S., Lo, Y.F., Wu, C.C., Lin, S.W., Yeh, C.J., Chu, P., Sytwu, H.K., Uchida, S., Sasaki, S., and Lin, S.H. (2010). SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. *J. Am. Soc. Nephrol.* *21*, 1868–1877.

Dietary Salt Intake Regulates WNK3–SPAK–NKCC1 Phosphorylation Cascade in Mouse Aorta Through Angiotensin II

Moko Zeniya, Eisei Sohara, Satomi Kita, Takahiro Iwamoto, Koichiro Susa, Takayasu Mori, Katsuyuki Oi, Motoko Chiga, Daiei Takahashi, Sung-Sen Yang, Shih-Hua Lin, Tatemitsu Rai, Sei Sasaki and Shinichi Uchida

Hypertension. 2013;62:872-878; originally published online September 9, 2013;

doi: 10.1161/HYPERTENSIONAHA.113.01543

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2013 American Heart Association, Inc. All rights reserved.

Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://hyper.ahajournals.org/content/62/5/872>

Data Supplement (unedited) at:

<http://hyper.ahajournals.org/content/suppl/2013/09/09/HYPERTENSIONAHA.113.01543.DC1.html>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:

<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Hypertension* is online at:

<http://hyper.ahajournals.org/subscriptions/>

Dietary Salt Intake Regulates WNK3–SPAK–NKCC1 Phosphorylation Cascade in Mouse Aorta Through Angiotensin II

Moko Zeniya, Eisei Sohara, Satomi Kita, Takahiro Iwamoto, Koichiro Susa, Takayasu Mori, Katsuyuki Oi, Motoko Chiga, Daiei Takahashi, Sung-Sen Yang, Shih-Hua Lin, Tatemitsu Rai, Sei Sasaki, Shinichi Uchida

Abstract—Na–K–Cl cotransporter isoform 1 (NKCC1) is involved in the regulation of vascular smooth muscle cell contraction. Recently, the with-no-lysine kinase (WNK)–STE20/SPS1-related proline/alanine-rich kinase (SPAK)–NKCC1 phosphorylation cascade in vascular smooth muscle cells was found to be important in the regulation of vascular tone. In this study, we investigated whether the WNK–SPAK–NKCC1 cascade in mouse aortic tissue is regulated by dietary salt intake and the mechanisms responsible. Phosphorylation of SPAK and NKCC1 was significantly reduced in the aorta in high-salt–fed mice and was increased in the aorta in low-salt–fed mice, indicating that the WNK–SPAK–NKCC1 phosphorylation cascade in the aorta was indeed regulated by dietary salt intake. Acute and chronic angiotensin II infusion increased phosphorylation of SPAK and NKCC1 in the mouse aorta. In addition, valsartan, an antagonist of angiotensin II type 1 receptor, inhibited low-salt diet–induced phosphorylation of SPAK and NKCC1, demonstrating that angiotensin II activates the WNK–SPAK–NKCC1 phosphorylation cascade through the angiotensin II type 1 receptor. However, a low-salt diet and angiotensin II together did not increase phosphorylation of SPAK and NKCC1 in the aorta in WNK3 knockout mice, indicating that activation of the WNK–SPAK–NKCC1 phosphorylation cascade induced by a low-salt diet and angiotensin II is dependent on WNK3. Indeed, angiotensin II–induced increases in blood pressure were diminished in WNK3 knockout mice. In addition, decreased response to angiotensin II in the mesenteric arteries was observed in WNK3 knockout mice. Our data also clarified a novel mechanism for regulation of vascular tonus by angiotensin II. Inhibition of this cascade could, therefore, be a novel therapeutic target in hypertension. (*Hypertension*. 2013;62:872–878.) • **Online Data Supplement**

Key Words: angiotensin II ■ aorta ■ NKCC1 ■ SPAK ■ WNK

Na–K–Cl cotransporter isoform 1 (NKCC1) is involved in the regulation of vascular smooth muscle cell contractions via intracellular Cl[−] accumulation, membrane depolarization, and activation of voltage-gated Ca channels, leading to elevation of peripheral resistance.¹ Indeed, NKCC1 knockout mice showed lower blood pressure because of decreased vascular tonus only when mice were fed a low-salt diet, as compared with those fed a normal diet, although dietary salt intake does not affect blood pressure in wild-type mice.² This indicates that NKCC1 plays a key role in the regulation of myogenic tone in arteries by dietary salt intake.

Pseudohypoaldosteronism type II is an autosomal-dominant disease characterized by salt-sensitive hypertension, hyperkalemia, and metabolic acidosis.³ Mutations in with-no-lysine kinase 1 (WNK1) and WNK4 have been reported to cause

pseudohypoaldosteronism type II.⁴ It has been demonstrated previously that the WNK kinase family phosphorylated and activated oxidative stress-responsive kinase 1 (OSR1) and STE20/SPS1-related proline/alanine-rich kinase (SPAK), and that these OSR1/SPAK kinases could phosphorylate and activate NKCC and Na–Cl cotransporter (NCC), which are solute carrier 12a (SLC12a) family cotransporters. This regulation of SLC12 family members by WNK–OSR1/SPAK signaling was confirmed in vivo in various genetically engineered mouse models.^{5–10}

Recently, the WNK–OSR1/SPAK–NKCC1 phosphorylation cascade in vascular smooth muscle cells was also found to be important for maintenance of vascular tone. Bergaya et al,⁸ as well as our group,¹¹ reported decreased NKCC1 phosphorylation in the aorta and decreased myogenic tone in the mesenteric arteries in WNK1^{−/−} mice, indicating that WNK1 plays

Received April 12, 2013; first decision May 2, 2013; revision accepted August 14, 2013.

From the Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan (M.Z., E.S., K.S., T.M., K.O., M.C., D.T., T.R., S.S., S.U.); Department of Pharmacology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan (S.K., T.I.); and Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (S.-S.Y., S.-H.L.).

The online-only Data Supplement is available with this article at <http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.113.01543/-/DC1>.

Correspondence to Eisei Sohara, Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan. E-mail esohara.kid@tmd.ac.jp

© 2013 American Heart Association, Inc.

Hypertension is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.113.01543

Downloaded from <http://hyper.ahajournals.org/> at Tokyo Medical and Dental Univ on April 14, 2014